VIVIAN VU: Open Payments
NPI 1952578106 · METAIRIE, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$851 in 43 payments from 13 companies in 2025. Trend: 2023 $1,774 · 2024 $989 · 2025 $851
Food & beverage: $851
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 12 | $179 |
| AstraZeneca Pharmaceuticals LP | 5 | $167 |
| Novo Nordisk Inc | 6 | $109 |
| ABBVIE INC. | 4 | $90 |
| Exact Sciences Corporation | 3 | $62 |
| Intra-Sana Laboratories | 2 | $52 |
| Kowa Pharmaceuticals America, Inc. | 3 | $43 |
| Lilly USA, LLC | 2 | $38 |
| Paratek Pharmaceuticals, Inc. | 2 | $35 |
| Phadia US Inc. | 1 | $23 |
Products named: FARXIGA, REPATHA, OTEZLA, The Cologuard Plus Collection Kit, RELTONE 200 MG, QULIPTA, ZORYVE, UBRELVY.
Industry payments across LA — which companies pay providers there.
